PHCentral News is gathered daily to bring you the latest developments in pulmonary hypertension treatments and research as well as stories we think are useful on an array of topics.  Under current news, you will find a dynamic list of stories for the last thirty (30) days.  You will find older news stories in our archives.    Stories about specific treatments can also be found in the medical section.

If you run across a PH news story we've missed or important story with broad appeal, please send us the link and we'll make sure it gets added.   Send news:  contact/info+phcentral+org.

  • September 22, 2014
  • RV-pulmonary arterial coupling predicts outcome in patients referred for pulmonary hypertension
  • (Heart) Prognosis in pulmonary hypertension (PH) is largely determined by RV function. However, uncertainty remains about what metrics of RV function might be most clinically relevant. The purpose of this study was to assess the clinical relevance of metrics of RV functional adaptation to increased afterload.
  • VIDEO: Screen scleroderma patients annually for pulmonary hypertension
  • (Skin & Allergy News) Noninvasive tests can catch pulmonary problems early, and treatments are available to slow the progression of scleroderma. Dr. Dinesh Khanna, director of the University of Michigan’s Scleroderma Program in Ann Arbor, discussed how to perform scleroderma screening at a conference held by Global Academy for Medical Education. GAME and this news organization are owned by Frontline Medical Communications.
  • September 21, 2014
  • Treating Inflammation in PAH Using Antioxidant Inflammation Modulators
  • (Pulmonary Hypertension News) With the eminent clinical need for a new PAH therapy, an extensive body of leading academic scientists has been developing cutting edge investigations for production of novel drugs. Among those developing therapies for the disease, Reata Pharmaceuticals, Inc. is developing a novel class of drugs with potent transcriptional activity called antioxidant inflammation modulators (AIMs). The company has already focused early research collaborations involving the therapeutic use of AIMs in treating several diseases such as melanoma, lung cancer, Freidreich’s Ataxia, Mitochondrial Myopathies, and Radiation Dermatitis, as well as for RTA402 (also known an bardoxolone methyl), an AIM being tested and developed  as a potential therapy for treating the underlying inflammation in PAH.
  • Pulmonary Hypertension in Elders Usually Is Not Idiopathic Pulmonary Arterial Hypertension
  • (NEJM Journal Watch) Pulmonary hypertension is being diagnosed in a growing number of older adults, but whether this trend is due to pulmonary arterial hypertension (PAH; pulmonary hypertension not secondary to left heart disease or intrinsic lung disease) or alternate causes is unknown. Because therapies for PAH are unique, determining the etiology of pulmonary hypertension is important.
  • September 20, 2014
  • Two Drugs Better Than One for Pulmonary Hypertension
  • (Medscape) Combining ambrisentan (Letairis, Gilead Sciences, Inc) and tadalafil (Cialis, Eli Lilly and Company) reduces the risk for clinical failure in pulmonary arterial hypertension by 50% compared with either drug alone, results from the AMBITION trial suggest.
  • Safe Dosage Established For Experimental Pulmonary Arterial Hypertension Therapy
  • (Lung Disease News) United Therapeutics Corporation, a licensee of Pluristem Therapeutics Inc., announced that investigators have finished establishing the safe dosage for an experimental PAH therapy in a phase I study for the first of the three cohorts of patients.
  • September 19, 2014
  • Pulmonary Hypertension Targeted Therapy Shows Promise
  • (MPR) The high-density lipoprotein mimetic peptide 4F can successfully rescue advanced pulmonary hypertension in rodent models, according to a study published in Circulation.
  • N-acetylcysteine: no benefit in idiopathic pulmonary fibrosis
  • (PulmCCM) N-acetylcysteine showed no benefit over placebo in the treatment of idiopathic pulmonary fibrosis.
    PANTHER-IPF trial... in an epic demonstration. The more rigorously conducted PANTHER-IPF was stopped early in 2012 due to clear harm resulting from prednisone and azathioprine given to people with idiopathic pulmonary fibrosis.

    But one appendage of PANTHER-IPF was allowed to live on: the 81 patients taking N-acetylcysteine (which seemed safe enough), and their placebo-taking controls. Those results were announced at the American Thoracic Society 2014 meeting, and published in the New England Journal in May 2014:

    N-acetylcysteine showed no benefit over placebo in the treatment of idiopathic pulmonary fibrosis.
    The same national meeting and journal issue announced the exciting success of pirfenidone and nintedanib for slowing lung function decline in IPF, and possibly even preventing IPF exacerbations and extending life for people with idiopathic pulmonary fibrosis.
  • September 18, 2014
  • Mast Therapeutics’ AIR001 PAH Therapy All-Around Stellar in Phase 2 Clinical Trial
  • (PHNews) Overwhelmingly positive results of Mast Therapeutics, Inc.‘s Phase 2 clinical trial of AIR001 (sodium nitrite, or Aironite®) inhalation solution for pulmonary arterial hypertension will lead to the company’s pursuit of additional Phase 2 trials in the near future. All doses of AIR001 were well-tolerated by patients and provided improvements in clinically relevant health parameters.
  • Protein in 'good cholesterol' may be a key to treating pulmonary hypertension
  • (MedicalXpress) Oxidized lipids are known to play a key role in inflaming blood vessels and hardening arteries, which causes diseases like atherosclerosis. A new study at UCLA demonstrates that they may also contribute to pulmonary hypertension
    Using a rodent model, the researchers showed that a peptide mimicking part of the main protein in high-density lipoprotein (HDL), the so-called "good" cholesterol, may help reduce the production of oxidized lipids in pulmonary hypertension. They also found that reducing the amount of oxidized lipids improved the rodents' heart and lung function
  • September 17, 2014
  • Researchers Discover Ranolazine May Be a Viable PAH Therapy
  • (PHNews) In this study, the team of scientists proposed to understand whether PAH-induced myocardial remodeling leads to the enhancement of INAL and if treatment with ranolazine (RAN), a clinically available INaL blocker, could prevent late Na+ increase and PAH- induced myocardial remodeling. The study results showed that RAN administration blocked INaL enhancement completely and significantly decreased PAH- induced remodeling. Hence, this results support Ran’s therapeutic potential as a treatment for PAH associated pathology.
  • September 16, 2014
  • Can Pulmonary Hypertension Be Treated With a Plant?
  • (PHNews) A  team of researchers turned to nature for answers, experimenting with extracting a protective enzyme from plant leaves that may hold the key to making a novel treatment work
    Lead author and assistant research scientist at the University of Florida, Gainesville, Vinayak Shenoy, Ph.D., said that among all the available therapies for PH, none target the root of the disease...
  • September 15, 2014
  • Sarcoidosis-Associated Pulmonary Hypertension and Lung Transplantation for Sarcoidosis
  • (MedScape) Abstract

    Pulmonary hypertension (PH) is a significant complication of sarcoidosis, occurring in approximately 6 to > 20% of cases, and markedly increases mortality among these patients. The clinician should exercise a high index of suspicion for sarcoidosis-associated PH (SAPH) given the nonspecific symptomatology and the limitations of echocardiography in this patient population. The pathophysiology of PH in sarcoidosis is complex and multifactorial. Importantly, there are inherent differences in the pathogenesis of SAPH compared with idiopathic pulmonary arterial hypertension, making the optimal management of SAPH controversial. In this article, we review the epidemiology, diagnosis, prognosis, and treatment considerations for SAPH. Lung transplantation (LT) is a viable therapeutic option for sarcoid patients with severe pulmonary fibrocystic sarcoidosis or SAPH refractory to...
  • Pulmonary Arterial Hypertension Study Targets Abnormal Smooth Muscle Cell Growth
  • (PHNews) Dr. Chen and colleagues decided to investigate the molecular mechanisms behind the abnormal proliferation of smooth muscle cells in the pulmonary artery and discovered two ways that the proliferation could be inhibited. “The characteristic proliferation of cells that line the blood vessels in pulmonary hypertension is similar to the abnormal growth and reproduction of cells that form cancerous tumors,” said Dr. Chen.
  • September 14, 2014
  • Local and Systemic RAGE Axis Changes in Pulmonary Hypertension: CTEPH and iPAH
  • (Plos One) The molecular determinants of chronic thromboembolic pulmonary hypertension (CTEPH) and idiopathic pulmonary arterial hypertension (iPAH) remain poorly understood. The receptor for advanced glycation endproducts (RAGE) and its ligands: HMGB1 and S100A9 are involved in inflammatory disorders. We sought to investigate the role of the RAGE axis in patients with CTEPH undergoing pulmonary endarterectomy (PEA), iPAH undergoing lung transplantation (LuTX). The high pulmonary vascular resistance in CTEPH/iPAH results in pressure overload of the right ventricle. We compared sRAGE measurements to that of patients with aortic valve stenosis (AVS) – pressure overload of the left ventricle.
  • Vascular Receptor Autoantibodies in Pulmonary Arterial Hypertension Associated with Systemic Sclerosis
  • (ATS Journals) Systemic sclerosis (SSc)-associated pulmonary arterial hypertension (PAH) portends worse outcome than other forms of PAH. Vasoconstrictive and vascular remodeling actions of endothelin-1 (ET-1) and angiotensin II (Ang II) via endothelin receptor type A (ETAR) and angiotensin receptor type-1 (AT1R) activation are implicated in PAH pathogenesis.
  • September 13, 2014
  • Combining Gilead’s Ambrisentan and Tadalafil in PAH Clinical Trial Reduced Risk of Clinical Failure
  • (Pulmonary Hypertension News) When Gilead Sciences, Inc. initiated a clinical trial for first-line combination therapy for pulmonary arterial hypertension treatment, the company felt that their ambitious approach to developing a new, viable therapy for the disease was worthy of the clinical trial name “AMBITION.” Now, according to a news release from Gilead, the company is announcing positive results of the AMBrIsentan and Tadalafil in patients with pulmonary arterial hypertensION phase 3 clinical trial. The primary endpoint of time to first clinical failure event was reached, with the treatment group experiencing a 50% reduction in risk for an event.
  • Mast Therapeutics, Inc. (MSTX) Reports Positive Top Line Phase 2 Data on AIR001
  • (Street Insider) Mast Therapeutics, Inc. (NYSE: MSTX) today reported top-line results from a Phase 2 study of AIR001 (sodium nitrite) inhalation solution for the treatment of pulmonary arterial hypertension (PAH).
  • September 12, 2014
  • Blocking one receptor could halt rheumatoid arthritis
  • (Medical Xpress) Researchers at the University of Illinois at Chicago College of Medicine have shown for the first time how the activation of a receptor provokes the inflammation and bone degradation of rheumatoid arthritis—and that activation of this one receptor, found on cells in the fluid of arthritic joints, is all that is required...
  • Nebivolol and pulmonary hypertension
  • (ERS Conference 2014) According to the authors, this work demonstrates for the first time that nebivolol improves endothelial dysfunction, pulmonary vascular remodeling, and right heart function and could be a safe option for the management of PAH. Until clinical studies are undertaken, however, routine use of beta-blockers in PAH cannot be recommended.
  •  Information experiences and needs in patients with pulmonary arterial hypertension or chronic thromboembolic pulmonary hypertension.
  • (Nursing Research and Practice) Background. Pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH) are fatal, noncurable, but treatable diseases that strongly affect the patients. Objective. To describe patients' experience of information relating to PAH or CTEPH. Methods. A qualitative method using content analysis was applied.
    Conclusions. In the future, healthcare organizations must struggle to achieve a holistic healthcare by making it more person-centred, and they must also promote cooperation between PAH centres and local healthcare providers. It is essential to determine the most appropriate and valuable path of information and communication and, thereby, the most cost-effective management of PAH or CTEPH.
  • Use of nebivolol in patients with idiopathic pulmonary hypertension: results of the pilot study
  • (PUbmed) Te aim of a smaller Russian study was to study the impact of 24-week therapy with nebivolol in a dose of 5 mg/day on the clinical and functional status of patients with idiopathic pulmonary hypertension (IPH), echocardiographic parameters, and blood levels of vasoactive mediators and nitric oxide (NO) metabolite.

    The researchers concluded: "Therapy with nebivolol in a dose of 5 mg/day for 24 weeks led to a significant functional improvement in the patients with IPH and reductions in RV dimensions and blood ET-1 levels. The therapy did not cause adverse reactions."
  • September 11, 2014
  • Using plants to produce enzyme may provide treatment for high blood pressure in lungs
  • (Medical Xpress) "Current therapies for pulmonary hypertension don't cure the underlying disorder and the long-term prognosis is poor, even with treatment," said Vinayak Shenoy, Ph.D., the study's lead author and an assistant research scientist at the University of Florida in Gainesville. "There is an urgent need to discover potential new therapies that can stop the disease process." 
  • Safe Dosage Established For Experimental Pulmonary Arterial Hypertension Therapy
  • (Lung Disease News) Pluristem Therapeutics Inc. is a clinical-stage biotechnology company using placental cells to develop cell therapies in collaboration with companies like United Therapeutics and other research and clinical institutions to target inflammatory and ischemic conditions like peripheral artery disease, muscle injury, preeclampsia, and graft versus host disease.
  • September 10, 2014
  • Management of Sickle Cell Disease: Summary of the 2014 Evidence-Based Report by Expert Panel Members.
  • (JAMA) Click headline for reading the full text report.
  • Study sheds light on how stem cells can be used to treat lung disease
  • (Euro Alert (press release)) ARDS is a life-threatening condition in which the efficiency of the lungs is severely reduced. It is caused by damage to the capillary wall either from illness or a physical injury, such as major trauma. ARDS is characterised by excessive and dysregulated inflammation in the lung and patients require mechanical ventilation in order to breathe. 
  • September 9, 2014
  • United Therapeutics Advances to Second Cohort in Phase I Trial of Pluristem’s PLX-PAD Cells for Treatment of Pulmonary Arterial Hypertension
  • ( HAIFA, ISRAEL, September 08, 2014 --Pluristem Therapeutics Inc. (NasdaqCM: PSTI; TASE: PLTR), a leading developer of placenta-based cell therapy products, announced today that its licensee, United Therapeutics Corporation, has completed the dosing of the first cohort of patients in its Phase I study using Pluristem’s PLacental eXpanded (PLX-PAD) cells in patients diagnosed with pulmonary arterial hypertension (PAH). PAH, with a global market estimated at approximately $3 billion, is characterized by abnormally high blood pressure in the arteries of the lungs; it can disrupt lung and heart function, leading to debilitating conditions such as heart failure.

    The Phase I study, being conducted in Australia, is an open-label, dose-escalation study designed to enroll 9 patients diagnosed with PAH. The first cohort of 3 patients has received 0.5 million PLXcells per kilogram body weight. An independent Data Safety Monitoring Board recommended advancement to the second cohort. The second cohort will receive 1 million cells per kilogram, while the third cohort is planned to be administered 2 million cells per kilogram. The primary endpoint of the study is the safety of PLX-PAD cells, which will be evaluated at 12 weeks and one year after dosing. Secondary efficacy endpoints are to be measured at six weeks post-treatment in order to assess changes in the ability to exercise, disease severity and cardio-respiratory function; measures include six-minute walk distance and cardio-pulmonary hemodynamic parameters evaluated via right heart catheterization and echocardiogram...

  • Safety and Sustained Benefits of Adempas® From Bayer Confirmed by Results of Long-Term Studies
  • (Bayer Healthcare) Analysis of long-term extension studies CHEST-2 and PATENT-2 confirms long-term safety profile of riociguat over two years in patients with chronic thromboembolic pulmonary hypertension (CTEPH) and pulmonary arterial hypertension (PAH) / Results demonstrate sustained improvements with riociguat in patients with CTEPH and PAH. The 2-year survival was 93% for both, CTEPH and PAH patients..
  • New Targets for Treating Pulmonary Hypertension Found
  • ( Newswise — Two new potential therapeutic targets for the treatment of pulmonary arterial hypertension, a deadly disease marked by high blood pressure in the lungs, have been identified by researchers at the University of Illinois at Chicago. Their findings are reported in the American Journal of Respiratory and Critical Care Medicine...
  • September 8, 2014
  • Racial Difference in Sarcoidosis Mortality in the United States.
  • (CHEST) Background.The clinical presentation and outcome of sarcoidosis varies by race. However, the race difference in mortality outcome remains largely unknown. Methods.We studied mortality related to sarcoidosis from 1999 through 2010 by examining multiple-cause-of-death data from the National Center for Health Statistics...
  • September 7, 2014
  • Thrombocytopenia is an independent predictor of mortality in pulmonary hypertension
  • (Heart and Lung) Established prognostic factors for pulmonary hypertension (PH) include brain natriuretic peptide, troponins and hemodynamic measures such as central venous pressure and cardiac output. The prognostic role of thrombocytopenia, however, has yet to be determined in patients with PH. The aim of this study was to evaluate effect of thrombocytopenia on mortality in patients with PH.
  • New Omentin Study Sheds Light On PAH
  • (Pulmonary Hypertension News) Omentin, an adipocyte-derived cytokine, is a potential novel candidate to treat obesity-related cardiovascular disease. Dr. Kyosuke Kazama and colleagues from the School of Veterinary Medicine, Kitasato University, Japan, have shown for the first time that long term treatment for 14 days with omentin inhibits vascular structural remodeling and abnormal contractile in rats with Pulmonary Arterial Hypertension (PAH) induced by monocrotaline. The researchers used monocrotaline (MCT) to induce PAH. MCT is a toxic pyrrolizidine alkaloid of plant origin that, when administrated in small doses to rats, causes vascular pulmonary lesions similar to those observed in humans with chronic pulmonary vascular diseases.
  • September 6, 2014
  • Platelets Are Highly Activated in Patients of Chronic Thromboembolic Pulmonary Hypertension
  • (AHA Journals) Chronic thromboembolic pulmonary hypertension (CTEPH) is a fatal disease that is distinct from pulmonary arterial hypertension (PAH). Although CTEPH is characterized by obstruction of major pulmonary artery because of chronic thrombus, it remains unclear whether CTEPH is associated with prothrombotic condition.
  • Bosentan Makes No Impact on PH Associated With Fibrotic IIP
  • (Practical Reviews) PH is a commonly encountered problem in patients with advanced IIP and carries a significantly worse prognosis. Current expert consensus discourages use of PH-specific therapy for these patients. This randomized placebo-controlled trial of patients with PH and fibrotic IIP showed no benefit of treatment with bosentan. PVRi was chosen as the primary end point for the trial and, although PVRi is a strong predictor of mortality, it is not known whether a change in PVRi is associated with outcomes nor what a clinically significant change is. Another important consideration is the short duration of the trial. Perhaps longer trials are needed to demonstrate disease stability and/or improvement in hemodynamics in this patient population. At this point, bosentan should not be used to treat PH associated with fibrotic IIP.(Reviewer–Nadine Al-Naamani, MD).
  • September 5, 2014
  • Arena Pharmaceuticals' APD811 Granted Orphan Drug Status for Pulmonary Arterial Hypertension
  • (Arena) "The FDA Office of Orphan Products Development (OOPD) evaluates scientific and clinical data submissions from sponsors to identify and designate drug candidates that could potentially treat rare diseases to help advance the evaluation and development of such products," said Craig M. Audet, Ph.D., Arena's Senior Vice President, Operations & Head of Global Regulatory Affairs. "We are pleased with the OOPD's designation of orphan drug status for the active moiety of APD811, and we look forward to advancing this drug candidate into a Phase 2 clinical trial program later this year."
  • United Therapeutics Blocks Generic PAH Drug For Remodulin in Patent Case
  • (Pulmonary Hypertension News) First approved in the United States in May 2002, Remodulin is a prostacyclin vasodilator used for the treatment of pulmonary arterial hypertension. The therapy is typically used to decrease symptoms associated with exercise. In patients with PAH, Remodulin is indicated to diminish the rate of clinical deterioration. Since it is considered a specialty medication for a rare, orphan disease, a 20 ml dose of Remodulin may cost over $6,000. The high price point of the drug has therefore made it an attractive target for generic drug manufacturers, who would like to produce a generic form of Remodulin and undercut United Therapeutics’ leading name-brand version of the drug — a gambit that Sandoz recently attempted, and that UT moved to block in the courts.
  • Potential Therapy Targets for Pulmonary Hypertension ID’d
  • (Doctors Lounge) The high-density lipoprotein mimetic peptide 4F can successfully rescue advanced pulmonary hypertension in rodent models, according to a study published in Circulation.
  • Insmed To Present Novel Inhalation PAH Treatment at European Respiratory Society’s International Congress
  • (Pulmonary Hypertension News) Biopharm company, Insmed Incorporated, has announced that they will present their novel inhalation technologies for the treatment of orphan pulmonary diseases such as pulmonary arterial hypertension at the European Respiratory Society’s (ERS) International Congress 2014. Held between September 6th and 10th at the Internationales Congress Center München, in Munich, Germany, the congress will include several clinical and scientific presentations on respiratory diseases.
  • September 4, 2014
  • Key Data from Newly-Tested PAH Drug to be Presented at European Conference
  • (Pulmonary Hypertension News) The first results of AMBITION, a large pulmonary arterial hypertension clinical trial, will be presented this month at the European Respiratory Society (ERS) International Congress 2014, as part of the highlights of the meeting
  • September 3, 2014
  • Key protein lowering bad lipids may treat pulmonary hypertension
  • (The Health Site) A new study has found that oxidized lipids, may also contribute to pulmonary hypertension, a serious lung disease that narrows the small blood vessels in the lungs. The researchers at UCLA demonstrated using a rodent model that a peptide mimicking part of the main protein in high-density lipoprotein (HDL), the so-called ‘good’ cholesterol, may help reduce the production of oxidized lipids in pulmonary hypertension. They also found that reducing the amount of oxidized lipids improved the rodents’ heart and lung function. A rare progressive condition, pulmonary hypertension can affect people of all ages.
  • September 2, 2014
  • First recommendations on all new oral anticoagulants in pulmonary embolism published
  • (Medical Xpress) The first recommendations on the use of all new oral anticoagulants in pulmonary embolism are published today in new ESC Guidelines. The guidelines are launched at ESC Congress by Professor Stavros V. Konstantinides (Germany/Greece) and Professor Adam Torbicki (Poland).
  • September 1, 2014
  • USB Pulse Oximeter Device For COPD Receives FDA Clearance In The U.S.
  • (Lung Disease News) Minneapolis based Nonin Medical, Inc., inventor of finger pulse oximetry, announced Thursday that the U.S. Food and Drug Administration (FDA) has cleared the Nonin Model 3231 OEM/eHealth finger pulse oximeter for use in the United States, a medical device that can prove useful for patients suffering from COPD.
  • August 31, 2014
  • What's Going to Be Hot at ERS 2014
  • (Medscape) First results from AMBITION, the large pulmonary arterial hypertension trial, will be presented at the European Respiratory Society (ERS) International Congress 2014, which runs from September 6 to 10.
  • Pulmonary Hypertension Associated With Chronic Obstructive Lung Disease and Idiopathic Pulmonary Fibrosis
  • (Medscape) Severe pulmonary hypertension worsens the prognosis of patients with chronic obstructive pulmonary disease (COPD) or idiopathic pulmonary fibrosis (IPF). With the aim of better understanding the pathogenesis of this event and identifying the possible targets for therapeutic intervention, a great deal of clinical and translational research is now focused on this relevant field of medicine.
  • New Merger Bolsters Development of Drug For Idiopathic Pulmonary Fibrosis, a Disease Associated With PH
  • (Pulmonary Hypertension News) Although clinically unexplored, pulmonary hypertension (PH) in the setting of idiopathic pulmonary fibrosis (IPF) is a significant reality in many patients (32 to 85%).
  • August 30, 2014
  • ILH Opens Comprehensive Pulmonary Hypertension Center
  • (Healthcare Journal of New Oreleans) A new center offering specialized expertise for the diagnosis and treatment of pulmonary hypertension (PH), a rare and serious disease affecting the lungs, has opened in ILH’s University Medical Office Building, 2025 Gravier Street. Staffed by a multidisciplinary team of specialists from LSU and Tulane, the new Comprehensive Pulmonary Hypertension Center (CPHC) will offer seamless PH care, expert nursing support, access to PH research studies, patient support groups, and inpatient care should patients need to be hospitalized.
  • Characterization of right ventricular remodeling and failure in a chronic pulmonary hypertension model
  • (American Journal of Physiology) In pulmonary hypertension (PH), right ventricular (RV) dysfunction and failure is the main determinant of a poor prognosis. We aimed to characterize RV structural and functional differences during adaptive RV remodeling and progression to RV failure in a large animal model of chronic PH. Postcapillary PH was created surgically in swine (n=21).
  • August 29, 2014
  • Protein in 'good cholesterol' may be a key to treating pulmonary hypertension
  • (Medical Xpress) Oxidized lipids are known to play a key role in inflaming blood vessels and hardening arteries, which causes diseases like atherosclerosis. A new study at UCLA demonstrates that they may also contribute to pulmonary hypertension, a serious lung disease that narrows the small blood vessels in the lungs.
  • August 28, 2014
  • FDA Grants Clearance For Vibralung Acoustical Percussor Respiratory Device
  • (Lung Disease News) Westmed, Inc., a producer of respiratory medical devices, recently announced a 510 (k) clearance grant from the U.S. Food and Drug Administration to distribute the Vibralung Acoustical Percussor (VAP), a device designed to help patients with respiratory diseases or difficulties in releasing secretions from the lungs.
  • August 27, 2014
  • Pulmonary Hypertension & Viagra: Researchers Discover Novel Mechanisms of Sildenafil for Disease
  • (Pulmonary Hypertension News) Sildenafil, known more commonly by its brand name Viagra, is an inhibitor of phosphodiesterase type 5 (PDE-5), an enzyme found in various tissues and involved in the cardiovascular system, and is frequently used in the treatment of PH, since it can improve exercise capacity, PH symptoms, and haemodynamics. However, the molecular mechanisms behind the protective effect exerted by this drug are not fully understood. .
  • August 26, 2014
  • How accurate is the TR jet derived Pulmonary artery systolic pressure ?
  • (Venkatesan) Measuring TR peak velocity is the most popular  method to assess pulmonary arterial  pressure.It is  universally  believed  TR jet predicts the systolic PA pressure fairly accurately. By all means it is  a wrong perception.

    At best ,  it has only 40% correlation with cath  derived PAP...
  • New Report Identifies Key Features in Systemic Sclerosis and PAH
  • (PHNews) Systemic sclerosis (SSc) is a disease that affects multiple organs, with the heart being frequently affected. Different heart structures can be affected leading to pericardial disease, arrhythmias, conduction system abnormalities, direct myocardial disease such as pulmonary arterial hypertension.
  • August 25, 2014
  • Climate Change and Dust Increase Respiratory Disease
  • (Guardian Liberty Voice) The connection between dust, allergies, and asthma is clear, but the link between the increasing problem of respiratory disease and climate change is not. The confusing lack of clarity around this issue is exacerbated by mixed messages from the very sources that should be helping to clarify it– the U.S. government.
  • Novel Nitric Oxide Delivery System May Someday Improve PH Treatments
  • (PHNews) GeNo LLC,  is currently testing next-generation inhaled nitric oxide (NO) drug delivery systems for use in both hospital and outpatient settings that could come to impact treatments for those with pulmonary hypertension.
  • August 24, 2014
  • Gum Disease: a Matter of Life and Death?
  • (PR Wire) Most people are very familiar with the reality that, if they don't practice regular brushing and overall good dental hygiene, they are at risk for developing gum disease. Less well known is the full extent of the potential harm caused by gum disease. In addition to very unpleasant side effects including bad breath, mouth sores, and loss of teeth, research shows that the dangers of gum disease may have a negative impact on more than just your mouth. Recent studies have linked gum disease to other life threatening health concerns such as lung disease, cancer, and even heart failure. Dr. Peiman Soleymani of Beverly Hills Periodontics & Dental Implant Center, a leading specialist in periodontal disease in Los Angeles, wants to make sure the public is aware of these well documented but somewhat surprising dangers. 

News Archives
Take the Current Poll
View Current Poll Results To Date
View the Poll Archives